Botha J L, Bray F, Sankila R, Parkin D M
Trent Cancer Registry, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK.
Eur J Cancer. 2003 Aug;39(12):1718-29. doi: 10.1016/s0959-8049(03)00118-7.
Trends in the incidence of and mortality from breast cancer result from a variety of influences including screening programmes, such as those introduced in several European countries in the late 1980s. Incidence and mortality rates for 16 European countries are analysed. Incidence increased in all countries. The estimated annual percent change (EAPC) varied from 0.8 to 2.8% in prescreening years in 6 'screened' countries and from 1.2 to 3.0% in 10 'non-screened' countries. Screening related temporary increases were visible. Earlier mortality trends were maintained in the most recent decade in Estonia (EAPC +1.8%) and Sweden (-1.2%). In other countries, previously increasing trends changed. Trends flattened in Finland, Denmark, France, Italy and Norway (EAPC 0.0 to -0.3%), while they declined in England and Wales (-3.1%), Scotland (-2.0%), and The Netherlands (-1.0%), all of which have national screening programmes, and in Slovakia (-1.1%), Spain (-0.7%), and Switzerland (-1.1%). In some countries with screening programmes, declines in mortality started before screening was introduced, and declines also occurred in non-screened age groups and in some countries without national screening programmes. This suggests that the major determinants of the observed trends vary among the countries and may include earlier detection through screening in countries where this has been introduced, but also improvements in therapy, in countries with or without screening.
乳腺癌发病率和死亡率的趋势受到多种因素的影响,包括筛查项目,如20世纪80年代末在几个欧洲国家推行的那些项目。对16个欧洲国家的发病率和死亡率进行了分析。所有国家的发病率均有所上升。在6个“已筛查”国家,筛查前几年的估计年变化百分比(EAPC)在0.8%至2.8%之间,在10个“未筛查”国家则在1.2%至3.0%之间。与筛查相关的暂时上升是可见的。爱沙尼亚(EAPC +1.8%)和瑞典(-1.2%)在最近十年保持了较早的死亡率趋势。在其他国家,之前上升的趋势发生了变化。芬兰、丹麦、法国、意大利和挪威的趋势趋于平缓(EAPC为0.0%至-0.3%),而英格兰和威尔士(-3.1%)、苏格兰(-2.0%)、荷兰(-1.0%),这些国家都有全国性筛查项目,以及斯洛伐克(-1.1%)、西班牙(-0.7%)和瑞士(-1.1%)的死亡率则有所下降。在一些有筛查项目的国家,死亡率在引入筛查之前就开始下降,而且在未筛查年龄组以及一些没有全国性筛查项目的国家也出现了下降。这表明,观察到的趋势的主要决定因素在不同国家有所不同,可能包括在已引入筛查的国家通过筛查实现的更早检测,但也包括在有或没有筛查的国家治疗方面的改善。